AnaptysBio, Inc. (NASDAQ:ANAB) Shares Bought by Frazier Life Sciences Management L.P.

Frazier Life Sciences Management L.P. increased its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 2.0% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,209,189 shares of the biotechnology company's stock after acquiring an additional 43,598 shares during the period. AnaptysBio makes up about 3.0% of Frazier Life Sciences Management L.P.'s investment portfolio, making the stock its 13th biggest position. Frazier Life Sciences Management L.P. owned approximately 7.26% of AnaptysBio worth $74,008,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of ANAB. Assenagon Asset Management S.A. grew its holdings in shares of AnaptysBio by 38.2% in the 2nd quarter. Assenagon Asset Management S.A. now owns 306,633 shares of the biotechnology company's stock worth $7,684,000 after acquiring an additional 84,795 shares during the period. Bank of New York Mellon Corp grew its holdings in shares of AnaptysBio by 16.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 74,510 shares of the biotechnology company's stock worth $1,867,000 after acquiring an additional 10,423 shares during the period. Rhumbline Advisers grew its holdings in AnaptysBio by 1.8% during the 2nd quarter. Rhumbline Advisers now owns 29,715 shares of the biotechnology company's stock valued at $745,000 after buying an additional 525 shares during the last quarter. TD Asset Management Inc grew its holdings in AnaptysBio by 67.3% during the 2nd quarter. TD Asset Management Inc now owns 37,800 shares of the biotechnology company's stock valued at $947,000 after buying an additional 15,200 shares during the last quarter. Finally, Headlands Technologies LLC grew its holdings in AnaptysBio by 444.8% during the 2nd quarter. Headlands Technologies LLC now owns 3,552 shares of the biotechnology company's stock valued at $89,000 after buying an additional 2,900 shares during the last quarter.

Insider Buying and Selling

In related news, insider Paul F. Lizzul sold 1,500 shares of the stock in a transaction on Monday, September 23rd. The stock was sold at an average price of $38.67, for a total value of $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares in the company, valued at approximately $595,440.66. This represents a 8.88 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric J. Loumeau sold 8,720 shares of the stock in a transaction on Monday, September 16th. The shares were sold at an average price of $39.82, for a total value of $347,230.40. Following the completion of the sale, the insider now owns 7,020 shares of the company's stock, valued at approximately $279,536.40. This represents a 55.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 22,440 shares of company stock valued at $892,936. 33.70% of the stock is currently owned by company insiders.

Analyst Ratings Changes

ANAB has been the topic of a number of analyst reports. HC Wainwright lowered their target price on AnaptysBio from $55.00 to $52.00 and set a "buy" rating on the stock in a report on Wednesday, November 6th. UBS Group increased their target price on AnaptysBio from $23.00 to $33.00 and gave the company a "neutral" rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. lowered their target price on AnaptysBio from $75.00 to $66.00 and set an "overweight" rating on the stock in a report on Tuesday, November 12th. Wedbush reiterated an "outperform" rating and set a $42.00 target price on shares of AnaptysBio in a report on Thursday, November 14th. Finally, BTIG Research cut AnaptysBio from a "buy" rating to a "neutral" rating in a report on Monday, December 2nd. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $54.64.

AnaptysBio Stock Performance

Shares of ANAB traded up $0.21 during trading hours on Tuesday, hitting $23.09. The stock had a trading volume of 364,978 shares, compared to its average volume of 362,274. The firm has a market cap of $702.63 million, a P/E ratio of -3.80 and a beta of -0.11. The company's fifty day simple moving average is $26.72 and its 200 day simple moving average is $29.68. AnaptysBio, Inc. has a 12-month low of $15.84 and a 12-month high of $41.31.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share for the quarter, topping the consensus estimate of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to analyst estimates of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, sell-side analysts predict that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

AnaptysBio Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.